These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 27770339)
1. Co-morbidities Rather than Age Impact Outcomes in Patients Receiving Preoperative Therapy for Gastroesophageal Adenocarcinoma. Charalampakis N; Xiao L; Lin Q; Elimova E; Shimodaira Y; Harada K; Rogers JE; Mares J; Amlashi FG; Minsky BD; Das P; Hofstetter WL; Matamoros A; Sagebiel TL; Blum-Murphy MA; Lee JH; Weston B; Bhutani MS; Mansfield PF; Estrella JS; Badgwell BD; Ajani JA Ann Surg Oncol; 2017 Aug; 24(8):2291-2301. PubMed ID: 27770339 [TBL] [Abstract][Full Text] [Related]
2. Postoperative Morbidity and Mortality Rates are Not Increased for Patients with Gastric and Gastroesophageal Cancer Who Undergo Preoperative Chemoradiation Therapy. Badgwell B; Ajani J; Blum M; Ho L; Fournier K; Chiang YJ; Matamoros A; Das P; Mansfield P Ann Surg Oncol; 2016 Jan; 23(1):156-62. PubMed ID: 26059652 [TBL] [Abstract][Full Text] [Related]
3. The impact of neoadjuvant chemoradiotherapy on perioperative outcomes, tumor pathology, and survival in clinical stage II and III esophageal cancer. Markar SR; Bodnar A; Rosales J; Song G; Low DE Ann Surg Oncol; 2013 Nov; 20(12):3935-41. PubMed ID: 23892525 [TBL] [Abstract][Full Text] [Related]
4. Loss of Skeletal Muscle Mass During Neoadjuvant Chemoradiotherapy Predicts Postoperative Mortality in Esophageal Cancer Surgery. Reisinger KW; Bosmans JW; Uittenbogaart M; Alsoumali A; Poeze M; Sosef MN; Derikx JP Ann Surg Oncol; 2015 Dec; 22(13):4445-52. PubMed ID: 25893413 [TBL] [Abstract][Full Text] [Related]
5. Effect of Extending the Original Eligibility Criteria for the CROSS Neoadjuvant Chemoradiotherapy on Toxicity and Survival in Esophageal Cancer. de Heer EC; Hulshoff JB; Klerk D; Burgerhof JGM; de Groot DJA; Plukker JTM; Hospers GAP Ann Surg Oncol; 2017 Jul; 24(7):1811-1820. PubMed ID: 28188501 [TBL] [Abstract][Full Text] [Related]
6. Preoperative Therapy for Gastric Adenocarcinoma is Protective for Poor Oncologic Outcomes in Patients with Complications After Gastrectomy. Vicente D; Ikoma N; Chiang YJ; Fournier K; Tzeng CD; Song S; Mansfield P; Ajani J; Badgwell BD Ann Surg Oncol; 2018 Sep; 25(9):2720-2730. PubMed ID: 29987602 [TBL] [Abstract][Full Text] [Related]
7. Characteristics and Survival of Gastric Cancer Patients with Pathologic Complete Response to Preoperative Therapy. Stark AP; Ikoma N; Chiang YJ; Estrella JS; Das P; Minsky BD; Blum MM; Ajani JA; Mansfield P; Badgwell BD Ann Surg Oncol; 2019 Oct; 26(11):3602-3610. PubMed ID: 31350645 [TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08). Ruhstaller T; Thuss-Patience P; Hayoz S; Schacher S; Knorrenschild JR; Schnider A; Plasswilm L; Budach W; Eisterer W; Hawle H; Mariette C; Hess V; Mingrone W; Montemurro M; Girschikofsky M; Schmidt SC; Bitzer M; Bedenne L; Brauchli P; Stahl M; ; ; ; Ann Oncol; 2018 Jun; 29(6):1386-1393. PubMed ID: 29635438 [TBL] [Abstract][Full Text] [Related]
9. Adjuvant Chemotherapy vs Postoperative Observation Following Preoperative Chemoradiotherapy and Resection in Gastroesophageal Cancer: A Propensity Score-Matched Analysis. Mokdad AA; Yopp AC; Polanco PM; Mansour JC; Reznik SI; Heitjan DF; Choti MA; Minter RR; Wang SC; Porembka MR JAMA Oncol; 2018 Jan; 4(1):31-38. PubMed ID: 28975352 [TBL] [Abstract][Full Text] [Related]
10. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer. Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728 [TBL] [Abstract][Full Text] [Related]
11. Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach? Heger U; Blank S; Wiecha C; Langer R; Weichert W; Lordick F; Bruckner T; Dobritz M; Burian M; Springfeld C; Grenacher L; Siewert JR; Büchler M; Ott K Ann Surg Oncol; 2014 May; 21(5):1739-48. PubMed ID: 24419755 [TBL] [Abstract][Full Text] [Related]
12. Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours. Thomaschewski M; Hummel R; Petrova E; Knief J; Wellner UF; Keck T; Bausch D World J Gastroenterol; 2018 Apr; 24(13):1429-1439. PubMed ID: 29632424 [TBL] [Abstract][Full Text] [Related]
13. Advanced Age is Not a Contraindication for Treatment With Curative Intent in Esophageal Cancer. Voncken FEM; van der Kaaij RT; Sikorska K; van Werkhoven E; van Dieren JM; Grootscholten C; Snaebjornsson P; van Sandick JW; Aleman BMP Am J Clin Oncol; 2018 Sep; 41(9):919-926. PubMed ID: 28763327 [TBL] [Abstract][Full Text] [Related]
14. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Cats A; Jansen EPM; van Grieken NCT; Sikorska K; Lind P; Nordsmark M; Meershoek-Klein Kranenbarg E; Boot H; Trip AK; Swellengrebel HAM; van Laarhoven HWM; Putter H; van Sandick JW; van Berge Henegouwen MI; Hartgrink HH; van Tinteren H; van de Velde CJH; Verheij M; Lancet Oncol; 2018 May; 19(5):616-628. PubMed ID: 29650363 [TBL] [Abstract][Full Text] [Related]
15. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry. Münch S; Habermehl D; Agha A; Belka C; Combs SE; Eckel R; Friess H; Gerbes A; Nüssler NC; Schepp W; Schmid RM; Schmitt W; Schubert-Fritschle G; Weber B; Werner J; Engel J Strahlenther Onkol; 2018 Feb; 194(2):125-135. PubMed ID: 29071366 [TBL] [Abstract][Full Text] [Related]
16. CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT Tang H; Tan L; Shen Y; Wang H; Lin M; Feng M; Xu S; Guo W; Qian C; Liu T; Zeng Z; Hou Y; Yu Z; Jiang H; Li Z; Chen C; Lian C; Du M; Li H; Xie D; Yin J; Zhao N; Wang Q BMC Cancer; 2017 Jun; 17(1):450. PubMed ID: 28659128 [TBL] [Abstract][Full Text] [Related]
17. Cisplatin Substitution with Carboplatin During Radical Chemoradiotherapy for Oesophagogastric Carcinoma: Outcomes from a Tertiary Centre. Athauda A; Watkins D; Mohammed K; Chau I; Starling N; Rao S; Tait D; Aitken K; Cunningham D Anticancer Res; 2018 Oct; 38(10):5943-5949. PubMed ID: 30275223 [TBL] [Abstract][Full Text] [Related]
18. Impact of age on the feasibility and efficacy of neoadjuvant chemotherapy in patients with locally advanced oesophagogastric cancer. Sylvie L; Silvia S; Salah-Eddin AB; Markus F; Florian L; Peter TP; Bernhard H; Martin A; Alexander N Eur J Cancer; 2015 Sep; 51(14):1918-26. PubMed ID: 26216588 [TBL] [Abstract][Full Text] [Related]
19. Association Between Clinically Staged Node-Negative Esophageal Adenocarcinoma and Overall Survival Benefit From Neoadjuvant Chemoradiation. Gabriel E; Attwood K; Du W; Tuttle R; Alnaji RM; Nurkin S; Malhotra U; Hochwald SN; Kukar M JAMA Surg; 2016 Mar; 151(3):234-45. PubMed ID: 26559488 [TBL] [Abstract][Full Text] [Related]
20. Conditional survival in patients with esophageal or gastroesophageal junction cancer after receiving various treatment modalities. Deng W; Yang Z; Dong X; Yu R; Wang W Cancer Med; 2021 Jan; 10(2):659-674. PubMed ID: 33314798 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]